[go: up one dir, main page]

WO1999037764A3 - New members of the glypican gene family - Google Patents

New members of the glypican gene family Download PDF

Info

Publication number
WO1999037764A3
WO1999037764A3 PCT/EP1999/000329 EP9900329W WO9937764A3 WO 1999037764 A3 WO1999037764 A3 WO 1999037764A3 EP 9900329 W EP9900329 W EP 9900329W WO 9937764 A3 WO9937764 A3 WO 9937764A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene
glypican
primers
specific
fragments
Prior art date
Application number
PCT/EP1999/000329
Other languages
French (fr)
Other versions
WO1999037764A2 (en
Inventor
Mark Paul Dittmar Veugelers
Guido Joseph Frans David
Original Assignee
Vlaams Interuniv Inst Biotech
Mark Paul Dittmar Veugelers
Guido Joseph Frans David
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Interuniv Inst Biotech, Mark Paul Dittmar Veugelers, Guido Joseph Frans David filed Critical Vlaams Interuniv Inst Biotech
Priority to AU24229/99A priority Critical patent/AU2422999A/en
Publication of WO1999037764A2 publication Critical patent/WO1999037764A2/en
Publication of WO1999037764A3 publication Critical patent/WO1999037764A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to a novel polynucleotide encoding a new glypican-related protein ('glypican-6') and the gene for glypican-4 as well as derivatives of both genes for use in methods of diagnosis and therapy. Derivatives comprise for example fragments of the gene either isolated or synthetic and having a length that is smaller than the complete gene; primers, comprising at least 10 consecutive gene specific nucleotides, preferably about 20 gene specific consecutive nucleotides of the nucleotide sequence of the gene; longer oligonucleotides up to the full length of the gene; antisense variants of the gene, the fragments or the primers; antibodies directed to the gene, fragments, primers or complementary strands thereof; any specific ligand for DNA that can be used as a specific probe, peptide nucleic acid probes.
PCT/EP1999/000329 1998-01-27 1999-01-20 New members of the glypican gene family WO1999037764A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU24229/99A AU2422999A (en) 1998-01-27 1999-01-20 New members of the glypican gene family

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98200226.3 1998-01-27
EP98200226 1998-01-27

Publications (2)

Publication Number Publication Date
WO1999037764A2 WO1999037764A2 (en) 1999-07-29
WO1999037764A3 true WO1999037764A3 (en) 2000-02-03

Family

ID=8233325

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/000329 WO1999037764A2 (en) 1998-01-27 1999-01-20 New members of the glypican gene family

Country Status (2)

Country Link
AU (1) AU2422999A (en)
WO (1) WO1999037764A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1506406B1 (en) 2002-05-23 2009-03-11 Sunnybrook and Women's College Health Sciences Centre Diagnosis of hepatocellular carcinoma
WO2004022595A1 (en) * 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE
US7303914B2 (en) * 2003-01-30 2007-12-04 Hongyang Wang Monoclonal antibody against human hepatoma and use thereof
WO2006090136A2 (en) * 2005-02-22 2006-08-31 University Court Of The University Of Edinburgh Genetic screening of animals
AU2006277295B2 (en) * 2005-08-09 2011-08-11 Oncotherapy Science, Inc. Glypican-3 (GPC3)-derived tumor rejection antigenic peptides useful for HLA-A2-positive patients and pharmaceutical comprising the same
EP3245219B1 (en) 2015-01-16 2020-04-08 GlyP Holdings Pty Limited Glypican epitopes and uses thereof
EP3320773B9 (en) 2015-07-10 2023-10-11 Chugai Seiyaku Kabushiki Kaisha Mouse having human cd3 gene substituted for endogenous cd3 gene
EP3502250B1 (en) * 2016-08-22 2024-04-24 Chugai Seiyaku Kabushiki Kaisha Gene-modified rodent expressing human gpc3 polypeptide
CN107338306A (en) * 2017-07-23 2017-11-10 嘉兴允英医学检验有限公司 A kind of kit for GPC1mRNA detection of expression
JP7053058B2 (en) * 2020-05-28 2022-04-12 グリピー ホールディングス ピーティーワイ リミテッド Glypican epitopes and their use

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 20 July 1996 (1996-07-20), HILLIER L ET AL: "zh83a06.r1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 427858 5' similar to SW:GLYP_HUMAN P35052 GLYPICAN PRECURSOR", XP002109642 *
DATABASE EMBL 25 July 1996 (1996-07-25), LIEW C C: "LL1806F Fetal heart, Lambda ZAP Express Homo sapiens cDNA clone LL1806 5' similar to K-glypican.", XP002109643 *
FILMUS J ET AL: "Identification of a new membrane-bound heparan sulphate proteoglycan", BIOCHEMICAL JOURNAL., vol. 311, 15 October 1995 (1995-10-15), LONDON, GB, pages 561 - 565, XP002109639, ISSN: 0264-6021 *
HUBER R ET AL: "Analysis of exon/intron structure and 400 kb of genomic sequence surrounding the 5'-promoter and 3'-terminal ends of the human glypican 3 (GPC3) gene", GENOMICS., vol. 45, no. 1, 1 October 1997 (1997-10-01), SAN DIEGO., US, pages 48 - 58, XP002109641, ISSN: 0888-7543 *
VEUGELERS M ET AL: "Characterization of glypican-5 and chromosomal localization of human GPC5, a new member of the glypican gene family.", GENOMICS., vol. 40, no. 1, 15 February 1997 (1997-02-15), SAN DIEGO., US, pages 24 - 30, XP002109640, ISSN: 0888-7543 *
WATANABE K.: "K-glypican: a novel GPI-anhcored heparan sulfate proteoglycan that is highly expressed in developing brain and kidney.", THE JOURNAL OF CELL BIOLOGY., vol. 130, no. 5, September 1995 (1995-09-01), pages 1207 - 1218, XP002109638 *

Also Published As

Publication number Publication date
WO1999037764A2 (en) 1999-07-29
AU2422999A (en) 1999-08-09

Similar Documents

Publication Publication Date Title
WO2000003685A3 (en) Nitrilase homologs
Kim et al. Drosophila NK-homeobox genes.
Nakabeppu et al. The basic region of Fos mediates specific DNA binding.
Koslowsky et al. Guide RNAs for transcripts with developmentally regulated RNA editing are present in both life cycle stages of Trypanosoma brucei
Travers RNA polymerase and T4 development
Dontsova et al. Stem-loop IV of 5S rRNA lies close to the peptidyltransferase center.
Marzluff et al. Isolation and characterization of two linked mouse U1b small nuclear RNA genes
EP1201676A3 (en) PNA-DNA-PNA chimeric macromolecules
BG100188A (en) DNA Sequencing Enzymes
WO1999064582A3 (en) High-throughput screening of gene function using libraries for functional genomics applications
EP2341058A3 (en) Oligonucleotide Analogues
WO2000066739A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO2001066597A3 (en) Inflammation-related gene
WO1998026093A3 (en) Fluorescent nucleotide analog hairpin formation for detection of nucleic acid hybridization
WO1999037764A3 (en) New members of the glypican gene family
WO1996015144A3 (en) Chromosome 21 gene marker, compositions and methods using same
FR2723950B1 (en) NUCLEOTIDE FRAGMENTS CAPABLE OF SPECIFICALLY HYBRIDIZING WITH RICKETTSIA DNA OR RNA AND THEIR USE AS PROBES OR PRIMERS.
WO1998006841A3 (en) Two human nsp-like proteins
Dunn et al. The transcription termination site at the end of the early region of bacteriophage T7 DNA
WO2003014388A3 (en) Method and nucleic acids for the analysis of colon cancer
Florent et al. A family of genes related to a new expression site-associated gene in Trypanosoma equiperdum
WO2002022874A8 (en) Oligonucleotides for labeling oligonucleotide probes and proteins
WO2000003013A3 (en) Gene and protein involved in liver regeneration
WO2005049793A3 (en) Methods and compositions for combinatorial approaches to cancer gene therapy
WO1996029407A3 (en) Cellubrevin homologs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA